Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00889382 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
A Phase 1 study of Ovarian Cancer and Solid Tumors, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 152
- Enrollment target
- 20
- Study locations
NCT00889382: Completed Phase 1 study of Ovarian Cancer and Solid Tumors, sponsored by Astellas Pharma.
NCT00889382 is a Phase 1 study of Ovarian Cancer and Solid Tumors that has completed, run by Astellas Pharma. The registered enrollment target is 152 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00889382, a Phase 1 study of Ovarian Cancer and Solid Tumors, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 152 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multi-center, randomized, open-label, phase 1/2 study of continuous weekly paclitaxel and escalating doses of intermittent or continuous OSI-906 in patients with recurrent/relapsed ovarian and other solid tumors.
Primary Outcome
Primary outcome measure for Phase 1 portion
Conditions Studied
Interventions
- DRUG Paclitaxel
- DRUG OSI-906
Study Locations (20)
Western Australia
- St. John of God Hospital, Bunbury - Bunbury
- Sir Charles Gairdner Hospital - Perth
- St. John of Gog Hospital, Subiaco - Subiaco
North Carolina
- Blumenthal Cancer Center - Main - Charlotte
- Duke University Medical Center - Durham
Victoria
- Frankston Hospital - Frankston
- Border Medical Oncology - Wodonga
Ontario
- Juravinski Cancer Center - Hamilton
- Princess Margaret Hospital - Toronto
Arizona
- Mayo Clinic - Scottsdale
California
- Department of Obstetrics and Gynecology, University of California, Irvine - Orange
Indiana
- Horizon Oncology Center - Lafayette
Louisiana
- Ochsner Clinic Foundation - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2009-08-05 |
| Est. Completion | 2014-08-25 |
| Phase | Phase 1 |
What the finished NCT00889382 record still lists
NCT00889382 is an interventional study that assigns participants to a tested intervention. The registered 152 participants enrollment target is mid-sized for trials with a published cap, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (79% lower).
The record links to 2 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which Paclitaxel is the first listed.
NCT00889382 names 20 study sites across 15 states, led by Western Australia, North Carolina, Victoria.
Frequently Asked Questions
What is clinical trial NCT00889382 about?
NCT00889382 is a clinical study titled "A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)". This is a multi-center, randomized, open-label, phase 1/2 study of continuous weekly paclitaxel and escalating doses of intermittent or continuous OSI-906 in patients with recurrent/relapsed ovarian and other solid tumors.
What is the current status of trial NCT00889382?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 152 participants. The study started on 2009-08-05. Estimated completion is 2014-08-25.
What conditions does trial NCT00889382 study?
This clinical trial studies the following conditions: Ovarian Cancer, Solid Tumors.
What interventions are being tested in trial NCT00889382?
The interventions under investigation include: Paclitaxel (DRUG), OSI-906 (DRUG).
Who is sponsoring clinical trial NCT00889382?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00889382 being conducted?
This trial has 20 study locations across Arizona, California, Indiana, Louisiana, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00889382's enrollment target sits among peer trials
152 119th of 322 higher than 204 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03328078 · 152 participants · Phase 1
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- NCT04458532 · 152 participants · NA
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
- NCT04858334 · 152 participants · Phase 2
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- NCT04993859 · 152 participants
Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI